Insights+: EMA Marketing Authorization of New Drugs in September 2022

The EMA approved 7 New Chemical Entity (NCE) and 4 Biologic Drugs in Sept 2022, leading to treatments for patients and advances in the healthcare industry In September 2022, the major highlights drugs were Imcivree approval for bardet-biedl syndrome, Opdualag for unresectable or metastatic melanoma, Ultomiris for generalised myasthenia gravis PharmaShots has compiled a list…

BySenior EditorOctober 26, 2022

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…

BySenior EditorJune 30, 2022

Insights+: The US FDA New Drug Approvals in November 2020

The US FDA has approved 5 NDAs and 1 BLA in Nov 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 96 novel products so far in 2020, including 6 in Nov 2020.…

BySenior EditorDecember 17, 2020

Insights+: EMA Marketing Authorization of New Drugs in September 2022

PharmaShots’ Key Highlights of Second Quarter 2022

Insights+: The US FDA New Drug Approvals in November 2020

Contact US

OUR INFORMATION

FOLLW US

Insights+: EMA Marketing Authorization of New Drugs in September 2022

PharmaShots’ Key Highlights of Second Quarter 2022

Insights+: The US FDA New Drug Approvals in November 2020

FOLLW US

Sign Up to Our Newsletter